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Abstract. Mutations in the p53 tumour suppressor gene are 
common in a wide range of human malignancies. In 
particular G-»T transversions in the p53 gene occur at a high 
frequency in lung cancer tumours and as the same mutagens 
maybe responsible for p53 mutations in head and neck 
squamous cell carcinomas, a preliminary investigation was 
carried out to establish if this may be the case. Codon 249 of 
the p53 gene has been found to be a hot spot of G-»T 
transversions in hepatocellular carcinomas, thus it was 
decided to initially investigate this site using specific primers 
and restricting the PCR product with the Haelll restriction 
endonuclease. Fifty seven squamous cell carcinomas of the 
head and neck were investigated using this technique and no 
mutations were found at codon 249 in the p53 gene. In this 
study twenty six of the specimens were also examined 
immunohistochemically using a number of antibodies to p53 
(PAb 421, PAb 1801 and CM-1), and 19 were found to have 
positive staining. Moreover as positive p53 staining is 
considered to be synonymous with p53 mutations, over two 
thirds of our earlier immunohistochemical study indicated 
p53 mutations in head and neck tumours. The technique used 
in this paper has the advantage of scanning a large number of 
tumours for mutations at suspect sites and maybe of use in 
the future if specific mutational hot spots are found in the 
p53 gene in head and neck cancers. In the meantime p53 
mutations in these tumours are been investigated by 
conventional sequencing techniques. 
Introduction 
Aberrant p53 expression is now considered to be one of the 
commonest genetic events in a wide range of human cancers (1). 
The development of a number of antibodies to the p53 gene 
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product has enabled many groups to utilise 
immunohistochemical methods to estimate the frequency of 
p53 over-expression in human tumours. Over-expression of 
the p53 gene has been considered to be synomous with p53 
mutations, as mutations in this gene generally increase the 
stability of the p53 protein (2). However it is now recognised 
that certain tumours may not accumulate p53 protein but may 
still be mutant in the p53 gene, due to inactivated expression 
of both alleles or point mutations that do not stabilise the 
protein.(3-6). 
P53 mutations were recently reviewed by Hollstein et al 
(1) and they demonstrated that 98% of the 280 base 
substitutions analysed fell within 600 base pairs of the p53 
gene - from codons 110 to 307, encompassing exons 5 to 8 
inclusive. In particular these authors pointed out that the 
spectra of p53 mutations differed depending on the tumour 
type and that analysis of the specific nucleotide substitutions 
may provide clues to the etiology of these tumours. 
P53 expression has been analysed in squamous cell 
carcinomas of the head and neck using a number of antibodies 
(7). Overexpression of p53 was found in 49/73 (67%) (8) and 
16/34 (34%) (9) of these tumours. Apart from two head and 
neck cell lines there is no published information on the 
location of these p53 mutations. Overexpression of the p53 
gene has not been shown to correlate with any of the 
clinicopathological parameters in head and neck cancer (8) 
however it has been shown to correlate with a history of heavy 
smoking and heavy drinking (10). 
In lung tumours G->T transversions have been found in 
56% of cases (3) and these mutations were not found to be 
clustered at any one particular site within the p53 gene. In 
view of the epidemiological evidence for the etiology of both 
lung cancer and head and neck cancer, it is feasible that a 
similar mutagen maybe acting at both of these cancer sites 
and a high proportion of G->T transversions in the p53 gene 
may also be found in head and neck cancer. We decided to 
study one specific site in the p53 gene that has been 
previously shown to have a high frequency of G-»T 
transversions. A mutational hotspot has been found in 
hepatocellular carcinomas in the Qidong region in China (11) 
and in Southern Africa (12), where 12/26 patients had G-»T 
transversions at codon 249 in the p53 gene. Also mutations in 
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p53 sequence with wild co-don 249 
5' .GTTGGCTCTGACTGTACCACCATC ATCATCACACTGGAAGACTCCAG.. . 3 ' 
5' GTTGGCTCTGACTGTACCAC 3' primers 3' T/AGTGTGACCTTCTGAGGTC 5' 
18004R 18005 
PCR 
5 ' GTTGGCTCTGACTGTACC . . .AGgÇCCATCCTCACCATCATCACACTGGAAGACTCCAG 
Hae i n site (110 bp) 
Hae III digestion 
GTTGGCTCT AACCGGAGG and CCCATCCTOACCATCATCACACTGGAAGACTCCAG 
(75 bp) (35 bp) 
Figure I. Primers used to amplify the p53 gene in the region of codon 249. A natural Hae III site exists in the wild type 249 codon. 
1 2 3 4 1 2 3 
s 
Figure 2. R.F.L.P. analysis of head and neck squamous cell carcinoma 
specimens. A. Lane (1) pUC HaelH molecular weight marker, (2) amplified 
PCR product, patient number 271 (3-4) digested PCR products from patient 
numbers 271 and 74. B. (1) digested PCR product from patient number 274, 
(2) amplified PCR product, patient number 277, (3) cpx 174 HaelH 
molecular weight marker. 
single samples of cancer of the lung, breast and oesophagus 
have been reported at this site (1). 
We have used a new and sensitive technique for the 
detection of p53 mutations at codon 249, based on the 
existance of a HaelH restriction site at the wild type for 
codon 249, PCR product. 
Materials and methods 
Tumour specimens. Fifty seven squamous cell carcinomas of 
the oral cavity, larynx and pharynx were examined for a p53 
mutation at codon 249. Forty one specimens of patients were 
snap frozen at the time of surgery. Also a number of tumour 
specimens were analysed from 16 patients at different stages 
of chemotherapy treatment. The latter specimens were all 
paraffin embedded. Clinical and pathological parameters and 
follow up data were available for all of the patients analysed. 
DNA specimens. DNA was extracted from frozen tumour and 
normal tissue specimens by the methods previously described 
(14) Specimens that were fixed by formalin in paraffin 
embedded sections were extracted by boiling in a lysis 
buffer. 
Oligonucleotide primers and probes. The oligodeoxy-
nucleotides were synthesised by the solid phase triester method. 
Polymerase chain reactions. In vitro enzymatic DNA 
amplification (PCR) was performed on an automated thermal 
cycler using the methods described by Saiki et al (15). Thirty 
five reaction cycles were used, each of 30sec. at 95°C, 30sec. 
at 58°C and 50sec. at 72°C. Primers were designed to be used 
for the PCR amplification of the p53 region surrounding 
codon 249. The PCR was performed with the two primers 
and a HaelH recognition site existed if p53 codon 249 was 
wild type (Fig. 1). However the HaelH recognition site would 
not be formed if there was a mutation at codon 249. This 
approach is similar to that described by Haliassos et al (13). 
An aliquot of the PCR reaction product was first run on a 2% 
agarose gel for the presence of the amplified fragment 
(HObp). In the case of a wild type sequence at codon 249, 
the PCR product gave two fragments (75bp) and (35bp) 
when digested with HaelH (Fig. 1). 
Antibodies. The rabbit antiserum CM-1 has been raised 
against full length p53 expressed in E.coli using a modified 
T7 based expression vector (16) such that the first 
methionine of p53 was the initiation codon. This resulted in 
an expression vector that encodes a full length p53 protein 
that is not fused to any of other protein sequences (17). The 
CM-1 antibody was used at a concentration of 1 in 50 (IRL). 
The avidin-biotin (ABC) technique was used to stain the 
paraffin embedded sections with the CM-1 antibody (18). 
Control slides omitting the first antibody were used as 
negative controls as well as using an irrelevant mouse 
monoclonal antibody. Positive controls included the 
MRSV3.1 human breast cell line immortalised with a 
retroviral vector carrying the SV-40 large Τ antigen gene 
(obtained from Dr Joyce Taylor-Papadimitriou ICRF). Ρ Ab 
421 and PAb 1801 (Oncogene Science) antibodies were also 
used to determine p53 expression on a selection of these 
tumours as previously described in Field et al (8). 
INTERNATIONAL JOURNAL OF ONCOLOGY 1: 253-256, 1992 255 
ν 
'':> 
w 
» ·* 
t . 
% 
. 
# · 
.·« 
' \ * 
S: 
Λ ·/ 
A # 
*# #Ä»f.i» 
É ir»*
 f 
Wk 
Figure 3. A. Infiltrating squamous cell carcinoma of the head and neck (Patient number 280) stained with p53 CM-1 antibody showing all of the neoplastic 
cells with intense nuclear staining (x 250). B. Higher magnification of the previous Figure 3.A showing neoplastic cells with intensely stained nuclei. The 
normal cells of the adjacent are unstained (x400) 
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Results 
Fifty seven squamous cell carcinomas were examined for a 
mutation in the p53 gene at codon 249. Representative 
tumours are demostrated in Fig. 2. of patients 74, 271, 274 
and 277. All the patients examined demonstrated two wild 
type alleles. In Fig. 2, DNA from patient number 271 is 
amplified in lane A2 with the primers for the p53 249 codon 
site and digested with Haelll in lane A3. No mutations at 
codon 249 were observed in any of the 57 tumour specimens 
analysed in this study. 
Twenty six of the squamous cell carcinomas were also 
examined immunohistochemically for p53 expression, a 
number of which have been previously reported (8) using 
PAb 421 and PAb 1801. We have now analysed 40 
squamous cell carcinomas with the CM-1 p53 antibody 
(Field et al in preparation) and have found very similar 
staining results with this antibody as has been previously 
reported with PAb 420 and PAb 1801 antibodies, when using 
the same specimen blocks. An example of a positively 
staining squamous cell carcinoma using the CM-1 antibody 
is shown in Fig. 3. In this paper 19 known positive stained 
and seven known negatively stained squamous cell 
carcinomas were analysed for a mutation at codon 249. In 
addition a further 31 head and neck squamous cell 
carcinomas were analysed for a mutation at 249. 
Discussion 
Point mutations in the p53 gene at codon 249 in head and neck 
squamous cell carcinomas would appear to be very rare events 
as we have found no evidence of a mutation at this codon in 57 
tumour specimens analysed. Within this group of patients we 
have evidence for p53 positive staining in 19 tumours. Based 
on our previous findings over two thirds of head and neck 
tumours overexpress the p53 gene (8), therefore 38 of these 
tumours would probably stain positively with a p53 antibody. 
In addition it is now considered that overexpression of the p53 
gene product probably underestimates the p53 mutation rate in 
human tumours (3-6). 
This study was part of a larger investigation into p53 
expression in patients undergoing chemotherapy 
treatment for head and neck cancer (Field et al in 
preparation) of which two of these patients have had 
surgery or biopsies prior and post chemotherapy. Both of 
these patients were found to over-express the p53 product 
using the CM-1 antibody, prior and post treatment with 
chemotherapeutic agents, however neither of them had a 
mutation at codon 249. The technique used in this paper 
is both sensitive and specific for the detection of point 
mutations and has been previously used successfully to 
detect specific mutations in other genes (13,19). 
However, it appears that the more time consuming 
technique of sequencing the p53 gene in squamous cell 
carcinomas of the head and neck is required to determine 
the particular mutations in these tumours and this is 
presently been undertaken in our laboratory. In time the 
sequencing data on these tumours may provide clues as to 
whether specific p53 mutations are associated with a 
particular carcinogen in head and neck cancers (20). 
IN HEAD AND NECK CARCINOMA 
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